3 Carbon Extractions Enters into Collaboration with CannabisWise Accreditation

Vancouver, British Columbia, CANADA

VANCOUVER, British Columbia, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that 3 Carbon Extractions Inc. (“3 CARBON”), an industry leader in regulatory compliant cannabis hydrocarbon extraction solutions, has entered into a collaboration with CannabisWise to provide expert advice on standards for cannabis extracts.

3 Carbon will advise them on quality assurance standards for light hydrocarbon-based manufacturing and extraction methods.

CannabisWise is an accreditation program established by the BC based National Institute for Cannabis Health and Education (NICHE) earlier this year in response to Canada’s plan to legalize cannabis. This voluntary program is to set quality standards for various industry sectors in the post-prohibition marketplace, including cannabis extraction. 

For more information about CannabisWise’s accreditation program, please visit their website at: CannabisWise

3 Carbon Extractions CEO Phillip Kwong said, “We are excited to be collaborating with this exciting initiative. With Cannabis Wise, our sector will ensure consumers have access to more information and cannabis products that are the result of rigorous quality control standards at all stages of the process.”

Veritas Pharma has 50% stake in 3 Carbon and its CEO, Dr. Lui Franciosi stated: “We share the same view with Phillip as well as NICHE’s CEO Barinder Rasode, in that there is a need to know the origins of products being sold, whether recreational or medical. They should come from a legal source, be tested for proper consumer labelling about ingredients and usage, and any health claims on product labels should be supported by scientific evidence.”

About Veritas Pharma Inc.
Veritas Pharma Inc. is an emerging pharmaceutical and IP development company, who, through its 100% owned subsidiary Cannevert Therapeutics Ltd. (“CTL“), is advancing the science behind medical cannabis. It is the Company’s aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas’ investment in CTL is led by a strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent protect IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion-dollar markets according to Deloitte’s Insights and Opportunities.

Veritas Pharma Inc. is a publicly traded company in Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.

The Company would also like to announce the issuance of 2,000,000 stock options to directors, officers, and consultants priced at $0.23 for a term of twelve (12) months.

For more information, please visit our website: veritaspharmainc.com

On behalf of the Board of Directors

"Dr. Lui Franciosi"
Dr. Lui Franciosi
President and Chief Executive Officer

Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com.

Investor and Public Relations Contact
Veritas Pharma Inc.
Sam Eskandari
Telephone: +1.416.918.6785
Email: ir@veritaspharmainc.com
Website: www.veritaspharmainc.com 

The CSE has not reviewed, nor approved or disapproved the content of this press release.